PTPRC and renal cell adenocarcinoma: As described previously for renal cell cancer patients (Vroling et al, 2009), two distinct CD34+ cell populations, which differ in the expression of the leucocyte marker CD45 and progenitor marker CD133, were identified in NSCLC patients.